pexidartinib + eribulin

Plexxikon MOA pexidartinib-eribulin

Targeted Indication Status Sites link to clinicaltrials.gov

Metastatic
Breast Cancer

Phase 2

San Francisco, CA
Nashville, TN
Durham, NC

NCT01596751

These compounds and/or uses are investigational and have not been approved by the FDA or any other regulatory authority for the uses under investigation. Image above depicts proposed targeted pathway of the investigational agent(s) in the targeted indication.

Denardo DG et al. Cancer Discovery. 2011; 1(1); 0F53-65. Quail DF, Joyce JA. Nat Med. 2013; 19(11); 1423-37.